Bluepharma and iLoF join forces to accelerate the development of personalized medicines

iLoF, a pioneering leader in Optomics®—the technological platform that combines Artificial Intelligence and photonics to develop personalized solutions for clinical research and drug development—announces today a strategic collaboration with Bluepharma, a pharmaceutical company specialized in the research, development, and manufacturing of innovative healthcare products.

This partnership aims to explore, assess, and develop joint opportunities for applying Optomics® across the pharmaceutical value chain, particularly in the areas of drug development, R&D, and manufacturing.

Through this collaboration, Bluepharma strengthens its commitment to innovation, notably by integrating Artificial Intelligence technologies into pharmaceutical development. For iLoF, the partnership validates Optomics® as a technological differentiator, capable of providing highly precise critical data and accelerating drug development and the discovery of new therapeutic approaches. Under the agreement, Optomics® will be implemented in real-world contexts and evaluated according to regulatory requirements and strict quality standards across the entire pharmaceutical value chain.

According to António Lucas Nunes, Director of Scientific Innovation and Strategic Partnerships at Bluepharma:

"Innovation is in Bluepharma’s DNA. In partnership with iLoF, we are exploring how cutting-edge photonics and Artificial Intelligence can enhance our ability to develop complex formulations faster and with greater precision. This collaboration underscores our commitment to adopting technologies that are shaping the future of pharmaceutical development."

For Sara Rocha, Director of Strategy and Partnerships at iLoF:

"While AI has transformed drug discovery, integrating these technologies into physical drug development and manufacturing remains a challenge for the industry. Implementing Optomics® is a key step in building a sustainable and intelligent infrastructure for drug development. By digitizing and optimizing complex R&D and manufacturing processes, we are strategically addressing critical obstacles, improving the efficiency of pharmaceutical and technological development."

Sara Rocha also highlighted the broader impact of this synergy, stating that it will “drive the pharmaceutical industry into the era of true personalized medicine, ensuring that innovative therapies are developed with greater precision and delivered to patients more reliably.”